Abstract
In 2008, the global breast biopsy device market, which comprises vacuum
-assisted biopsy (VAB) devices, core needle biopsy (CNB) devices, fine needle
aspiration (FNA) devices, and breast biopsy markers sold in the US, Europe
(France, Germany, Italy, and the UK,) and Japan, grew to nearly $400 million
Demographic trends putting women at increased risk for breast cancer, combined
with the growing compliance with breast screening programs worldwide, will
continue driving biopsy procedure volumes
| 
View Cart
